Quanterix Corporation to acquire Akoya Biosciences, creating a groundbreaking integrated solution for ultra-sensitive detection of protein biomarkers
Acquiring Company
Quanterix
Acquired Company
Akoya Biosciences
BillericaMarlboroughOtherHealth CareOtherBiotechnologyHealth CareGeneticsHealth DiagnosticsBioinformaticsDescription
Quanterix Corporation, a leader in ultra-sensitive biomarker detection, has announced its definitive merger agreement to acquire Akoya Biosciences. This strategic acquisition is set to create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers, revolutionizing disease understanding and treatment.
Quick answer
Quanterix is acquiring Akoya Biosciences, announced January 10, 2025. Quanterix is based in Billerica, Massachusetts, United States.
- How much did Quanterix pay for Akoya Biosciences?
- The deal value was not disclosed.
- What does Quanterix do?
- Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health.
- Where are Quanterix and Akoya Biosciences based?
- Quanterix is based in Billerica, Massachusetts, United States. Akoya Biosciences is based in Marlborough, Massachusetts, United States.
- Who are the decision-makers at Quanterix?
- Fundz holds 1 contact at Quanterix. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Genetics and Health Diagnostics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- OraSure Technologies completes acquisition of Sherlock Biosciences, Inc. to expand its innovation pipeline in molecular testing market (December 19, 2024)
- GSK completes acquisition of IDRx, Inc. to enhance precision therapeutics for treating gastrointestinal stromal tumours (February 24, 2025)
- Flourish Research acquires Diablo Clinical Research to expand therapeutic coverage (February 18, 2025)
- Novartis to acquire Anthos Therapeutics for up to $3.1 Billion, $3.1B (February 11, 2025)
- Pan-Am Dental completes strategic acquisitions of JB Dental Lab and Avaneer Dental Studio, solidifying its position as a top 10 dental lab group (February 10, 2025)
- BioNTech completes acquisition of Biotheus to strengthen oncology strategy (February 4, 2025)
Who to call at Quanterix, and when
When Quanterix changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Quanterix raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Quanterix, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Quanterix. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Quanterix makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Akoya Biosciences?
Akoya Biosciences was acquired by Quanterix, based in Billerica. The deal was reported on January 10, 2025. Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. Quanterix is publicly traded (QTRX) and operates in Other.
When did Quanterix acquire Akoya Biosciences?
Quanterix's acquisition of Akoya Biosciences was reported on January 10, 2025. Quanterix Corporation, a leader in ultra-sensitive biomarker detection, has announced its definitive merger agreement to acquire Akoya Biosciences. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Akoya Biosciences do?
Akoya Biosciences is The Spatial Biology Company®, dedicated to advancing human health by providing spatial phenotyping solutions that bring biological context to life. It is privately held, operating in Other, and is based in Marlborough.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.